BioNTech on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said.
Posts
Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its makers said on Wednesday.
“Demand over the next five to 10 years will probably outstrip the current forecasts on supply,” said Thomas Breuer, GSK’s chief global health officer.